Medicament for treating B-cell lymphoma and for reduction of residual CD20+ tumor cells

摘要

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.